Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess the overall safety of lixisenatide once daily treatment in monotherapy over 24 and
52 weeks in patients with type 2 diabetes in Japan
Secondary Objective:
To assess the effects of lixisenatide once daily treatment in monotherapy over 24 and 52
weeks on:
- HbA1c (Glycated hemoglobin A1c) reduction;
- Fasting plasma glucose;
- Body weight.